We are currently conducting a thorough data analysis of Calliditas' Investor Relations page. By carefully studying traffic and user behaviors, we can identify areas for improvement. The goal is to create a better user experience for both current and potential shareholders, tailored to insights from our data analysis.

To WntResearch we created a landing page as well as a digital advertising strategy based on our database from previous campaigns. The landing page ensures that all the necessary information in relation to the issue is collected on one page, and that it measures how all channels perform and how well visitors convert to subscribe to the offer.

See the landing page for Wnt Research's issue here.

See the landing page we created for Ortoma's warrants of series TO 2 B. See Ortoma's new landing page here!

A few months ago we created website, Rhabarberum, the new training, life and philosophy concept that has taken place in Stockholm. This week we made some minor adjustments to the side and saw the side perform really well. It's fun!

See the Rhabarberum website.

In cooperation with Shark Communication we created a landing page dedicated to Spotlight Groups' rights issue. You can see the landing page here.

Our goal was to make it easy for new investors to have all the necessary info gathered in one place and easy to subscribe to the offer. We also measured campaign page data to see how the page performed.

After the subscription period, Cision shares the outcome on its website: ”The rights issue was subscribed for a total of approximately SEK 28.3 million, including subscription obligations of approximately SEK 12.3 million, which in total corresponds to a subscription rate of approximately 161 %. This means that Spotlight Group will receive approximately 17.6 MSEK before issuance costs, which are estimated to be less than 0.1 MSEK. A total of 704,363 shares will be issued through the rights issue. A total of 657,577 shares were subscribed under subscription rights, including subscription commitments of 487,912 shares. A total of 473,911 shares were subscribed without the support of subscription rights.”

In cooperation with Shark Communication we created a website to represent Staybles rights Issue. We measured a lot of new insights into ROI on marketing emails, marketing channels and campaigns for the rights issue. The rights issue was subscribed to 90%.

See the landing page we created for Staybles' rights issue here.

Audientes' rights issue was fully subscribed. See the landing page we created for Audientes here!

In cooperation with Shark Communication we created a promotion page for the rights issue.

Since the company is Danish and has many international players, we created the page in English. This promoted Audientes on various investor platforms and spread through their various social media platforms.

You can also read about the issue on the Börsverden website

We congratulate Audientes on this successful rights issue!

We created a new graphic profile and a new website for Cord Communications in less than a month. Cord Communications is a partner-owned communications advisor focused on IR and financial public relations.

It was a quick, smooth and fun project. See Cord Communications' website here!

Together with our partner, Shark Communication, we managed to create a refreshed graphic profile for Alzinova and greatly increased the retention of website visitors. This one we are very proud of. See the landing page for Alzinova's rights issue.‍

Ortoma's rights issue is live and the landing page we created for them has been launched. See Ortoma's new landing page here!

Safeture's rights issue was oversubscribed. See Safeture's landing page for the rights issue here.

We created, together with Shark Communication, a landing page for both new and current investors to easily subscribe to the rights issue offer.

We congratulate Safeture on a successful rights issue!

In cooperation with Lokon Pharma, we're now launching their new website.

Our task was to clearly and simply describe their research methods in immunotherapy.

We are impressed with their research, and wish them all the best in their future work.